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Abstract
Background: YKL-40 (chitinase-3-like-1) is a member of "mammalian chitinase-like proteins". The protein is
expressed in many types of cancer cells and the highest plasma YKL-40 levels have been found in patients with
metastatic disease, short recurrence/progression-free intervals, and short overall survival. The aim of the study
was to determine the expression of YKL-40 in tumor tissue and plasma in patients with borderline ovarian tumor
or epithelial ovarian cancer (OC), and investigate prognostic value of this marker.
Methods: YKL-40 protein expression was determined by immunohistochemistry in tissue arrays from 181
borderline tumors and 473 OC. Plasma YKL-40 was determined by ELISA in preoperative samples from 19
patients with borderline tumor and 76 OC patients.
Results: YKL-40 protein expression was found in cancer cells, tumor associated macrophages, neutrophils and
mast cells. The tumor cell expression was higher in OC than in borderline tumors (p = 0.001), and associated
with FIGO stage (p < 0.0001) and histological subtype (p = 0.0009). Positive YKL-40 expression (≥ 5% staining)
was not associated with reduced survival. Plasma YKL-40 was also higher in patients with OC than in patients
with borderline tumors (p < 0.0001), and it was positively correlated to serum CA-125 (p < 0.0001) and FIGO
stage (p = 0.0001). Univariate Cox analysis of plasma YKL-40 showed association with overall survival (p <
0.0001). Multivariate Cox analysis, including plasma YKL-40, serum CA125, FIGO stage, age and radicality after
primary surgery as variables, showed that elevated plasma YKL-40 was associated with a shorter survival (HR =
2.13, 95% CI: 1.40–3.25, p = 0.0004).
Conclusion: YKL-40 in OC tissue and plasma are related to stage and histology, but only plasma YKL-40 is a
prognostic biomarker in patients with OC.
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Background
YKL-40 (chitinase-3-like-1) is a highly conserved protein
[1] and a member of "mammalian chitinase-like proteins"
[1,2]. The protein is expressed in many types of cancer
cells (dbest NCBI database), and elevated plasma levels are
predictive of poor prognosis in patients with different
types of cancer [2-8]. The highest plasma YKL-40 levels
have been found in patients with metastatic disease, short
recurrence/progression-free intervals, and short overall
survival [2-8]. Furthermore, plasma YKL-40 has provided
independent information on prognosis over clinical char-
acteristics and biomarkers, such as serum CA-125, LDH,
PSA, CEA, and HER2 [2-8]. It has been suggested that YKL-
40 is associated with cancer cell proliferation, differentia-
tion, metastatic potential, and extracellular tissue remod-
elling, but in vivo proofs of these are yet to be obtained [2].
Immunohistochemical studies have demonstrated a
strong cellular expression of YKL-40 in all germ layers of
human embryos and fetuses, including ecto-, meso- and
endoderm [9]. The expression is particular high in tissues
characterized by rapid proliferation and marked differen-
tiation, and in tissues undergoing morphogenetic changes
[9]. A similar pattern is seen in normal adult human tis-
sue, where YKL-40 is highly expressed in cells with a high
cellular activity [10].
Neoplastic tissue has also been found to show a higher
expression for YKL-40 than the normal counterpart [2]. In
glioblastoma, YKL-40 protein expression has proven to be
a biomarker of histologic subtypes [11], with high gene-
and protein expression being associated with poor radia-
tion response and early disease progression and death
[11-13]. In addition, at recurrence YKL-40 is up-regulated
in the tumor tissue [14] and elevated in serum [15].
High YKL-40 protein expression has also been found in
carcinoma cells from breast [16-18], colon [2], liver [19],
cervix [2], and head/neck [20], and skin (melanoma) [2],
as well as within tumor-associated macrophages, mast
cells and leukocytes [10,18,20-22]. In a small study of
patients with breast cancer high YKL-40 protein expres-
sion in the cancer cells was associated with short disease-
free survival [16]. However, this could not be confirmed
in a recent large study of YKL-40 protein expression in
biopsies from 630 patients with primary breast cancer; in
this study there was no association between YKL-40 pro-
tein expression in the breast cancer cells and disease free
survival and overall survival [18].
There are no published studies on YKL-40 protein expres-
sion in OC tissue. Preoperative serum or plasma concen-
trations of YKL-40 are elevated in 65% of patients with
FIGO stage I and II, and in 74% to 91% of patients with
FIGO stage III and IV [23,24]. Patients with early-stage OC
[24], stage III [23], or recurrence of OC [25] and high
plasma or serum levels of YKL-40 have shorter survival
compared to patients with normal levels of YKL-40. No
close association between serum YKL-40 and serum CA-
125 and CA15-3 in patients with OC has been published
[23-26]. In patients with FIGO stage III multivariate Cox
analysis including preoperative plasma YKL-40, serum
CA125, optimal vs. suboptimal primary surgery, age, and
histological type of tumor, demonstrated that high
plasma YKL-40 was an independent biomarker of short
survival [23]. Furthermore, serum YKL-40 was a predictor
of chemoresistance in the second-line treatment of OC
patients [26].
The aim of this study was to determine YKL-40 tissue
expression in borderline and epithelial OC tissues, its pos-
sible correlation to clinical-pathological parameters and
plasma YKL-40 levels, and the prognostic value of both
YKL-40 tissue expression and plasma levels.
Methods
Patient Population
The MALOVA study ("MALignant OVArian cancer study")
is a multidisciplinary Danish study covering epidemiol-
ogy, lifestyle factors, biochemistry and molecular biology
with the purpose of identifying risk factors and prognostic
factors for OC. The design of the MALOVA study is
described in details elsewhere [27]. Briefly, preoperative
blood samples and tumor tissue samples were obtained
from the majority of the 681 OC patients and from the
235 women with borderline ovarian tumor were included
in the MALOVA study. FIGO stages were obtained from
clinical records and reviewed by two gynecologists spe-
cialized in OC. Patients were either classified as radically
operated with no macroscopic residual tumor or non-rad-
ically operated with macroscopic residual tumor after sur-
gery. On the retrospectively collected paraffin embedded
tissues, histologic grading were performed individually by
two persons.
Follow-up
In Denmark all inhabitants have a unique personal (10-
digit) identification number (CPR number), which is used
universally in the Danish society. These identification
numbers, which comprise information on date of birth
and sex, are registered in the computerized Danish
National Central Population Register. The register con-
tains information on e.g. dates of death and emigration.
All cases in this study were traced in the register and date
of death, emigration or August 23rd, 2007, whichever
came first, were registered. The relevant hospital files were
collected and scrutinized and information on treatment
(surgery and chemotherapy), was established. At the end
of follow-up, a total of 490 OC patients had died (median
follow-up time: 23 months, range: 1–111), and 191 OC
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patients were still alive (median follow-up time: 91
months, range: 66–121).
Tissue array
The paraffin embedded tissue from the tumors was used
for tissue array analyses. Forty-eight OC and 24 borderline
ovarian tumors were excluded because of poor tissue
quality or lack of tumor tissue in the collected blocks, and
132 OC and 16 borderline ovarian tumors were excluded
due to unreadable YKL-40 expression results, lack of
tumor cells in the selected TA cylinders, loss of tissue dur-
ing the staining procedure or folding/tearing of sections
by the microtome. Finally, 42 non-epithelial tumors (28
OC and 14 borderline ovarian tumors) were excluded
because epithelial and non-epithelial ovarian tumors dif-
fer in embryologic and pathologic characteristics.
Together, these exclusions left 473 OC and 181 borderline
ovarian tumors, which were suitable for the YKL-40 tissue
expression and survival analyses.
For the tissue array production, one to two representative
areas were marked on a freshly cut H&E stained section
from each selected block. Tissue cylinders with a diameter
of 2 mm were punched from corresponding areas in the
donor tumor block and brought into 2–4 individual
recipient paraffin blocks (tissue array blocks), using a cus-
tom-made manual Tissue Array Instrument (Beecher
Instruments, Silver Spring, MD, USA). Once the cores
were laid into the recipient block, the paraffin was slightly
melted in order to bind the cores into the block. This treat-
ment secured the cores during sectioning. Melting was
achieved by placing the blocks in an oven at 37°C for 10
min.
A total of 2 to 4 tissue arrays consisting of corresponding
viable and representative tissues from each ovarian tumor
were constructed in order to minimize the risk of intra-
tumor variability. The tissue arrays were sorted with
respect to histological subtype and FIGO stage. Four cores
of control tissue (2 from kidney, 2 from liver) were placed
strategically in each tissue array to ensure unique orienta-
tion of every tissue array together with a maximum of 31
different patient tumor samples.
Tissue preparation and immunostaining of YKL-40
Two μm sections (Section Transfer System, STS, Ergostar
HM200, MICROM International GmbH, Walldorf, Ger-
many) from the tissue array blocks were transferred to
glass slides (DAKO Chem-Mate Capillary Cap Microscope
Slides, 57 mm, DAKO A/S, Glostrup, Denmark). Slides
were stored at 4°C for a maximum of 8 days until staining
for YKL-40.
Prior to staining, the sections were deparaffinized in
xylene and rehydrated in graded dilutions of alcohol. In
order to demask antigens within the tissue, sections were
pretreated in TEG buffer, pH 9.0 (Tris 10 mmol/l and
EGTA 0.5 mmol/l), followed by heating in a microwave
oven to 98°C for 15 min. Sections were then left to cool
in the buffer at room temperature for an additional 15
min. To block endogen peroxidase activity the sections
were treated with 0.03% w/v hydrogen peroxide for 5
min. To avoid background staining the sections were then
pre-incubated with 5% w/v purified bovine serum albu-
min (BSA) (Dade Behring, Liederbach, Germany) diluted
in TRIS buffer pH 7.6 for 10 min. The primary specific
mouse monoclonal antibody against human YKL-40
(201.F9, 3.8 mg/ml, isotype IgG2b, κ, epitope GAWRGTT-
GHHS, corresponding to the amino acids 210–220) was
diluted 1:100 (38 ng/ml) in 1% w/v purified BSA (Dade
Behring) in TRIS buffer pH 7.6 and incubated for 60 min.
The secondary antibody EnVisionTM+System-HRP (DAB)
(Dako, Glostrup, Denmark, Code K 400711-2, lot no.
104.225) was used for 30 min. The colour was developed
with DAB added with chromogen for 10 min. Sections
were rinsed in water, counterstained in Mayers Hematox-
ylin for 3 min and finally dehydrated, mounted and cov-
erslipped with Pertex. Washings with 5 mM Tris buffer,
pH 7.6 with NaCl 0.9% w/v and Tween 0.1% v/v (TBS)
were used between all steps in the procedure. After heat-
ing all steps were performed at room temperature in a
humidity chamber to avoid air-drying of the sections. The
staining process was done manually.
YKL-40 scoring of tissue expression
Two observers, both experienced in evaluating immuno-
histochemical stained tissues, simultaneously assessed the
patterns of YKL-40 protein expression of each tumor sam-
ple. The observers had no knowledge of clinical parame-
ters and study endpoint. Standardization of scoring was
achieved by comparison of the scores, and any discrepan-
cies were resolved by consensus. Scoring for YKL-40 pro-
tein expression was based on the proportion of cells in a
given tumor specimen exhibiting distinct cytoplasmic
immunopositivity as well as the intensity of staining (per-
centage scale: 0, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, and
100). Secondly, the YKL-40 scoring results were trans-
formed into two scales: a two-tiered scale (1: negative; 2:
≥ 5% positive tumor cells) and a four-tiered scale (1: neg-
ative; 2: 5% positive tumor cells; 3: 10% positive tumor
cells; 4: ≥ 20% positive tumor cells). The four tissue con-
trol cores of kidney and liver, respectively, showed con-
sistent staining results. For the general description and the
prognostic evaluation both scales were used.
Plasma YKL-40 analysis
Blood samples were obtained no earlier than two weeks
prior to surgery from the 95 patients operated at Herlev
Hospital and Rigshospitalet, University of Copenhagen.
EDTA-blood samples were left on the blood cells at room
BMC Cancer 2009, 9:8 http://www.biomedcentral.com/1471-2407/9/8
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temperature for less than 8 hours. Following the samples
were separated by centrifugation at 2000 g for 10 min. at
room temperature and plasma EDTA samples stored in
aliquots at -80°C until analysis. EDTA plasma samples
collected from patients included in the MALOVA study,
who had been treated at other hospitals were not used for
plasma YKL-40 measurements, since the plasma obtained
from these centers had not been separated from the blood
cells within 8 hours after sampling. It is known that EDTA
plasma YKL-40 is only stable when samples are processed
within 8 hours [28].
Plasma levels of YKL-40 were determined in duplicates by
a commercial two-site, sandwich-type enzyme-linked
immunosorbent assay (Quidel, Santa Clara, CA, USA)
using streptavidin coated microplate wells, a biotinylated-
Fab monoclonal capture antibody, and an alkaline phos-
phatase-labeled polyclonal detection antibody. The detec-
tion limit was 20 μg/l. The intra-assay coefficient of
variation (CV) was ≤ 5.0% and inter-assay CVs ≤ 10.2%.
The samples were analyzed blinded to clinical parameters
and study endpoint.
Healthy subjects
The reference interval for plasma YKL-40 was determined
in 144 healthy women (median age 51 years, range 18–79
years) characterized by not being on medication and hav-
ing no signs of pre-existing disorders such as joint, liver,
metabolic or endocrine disease or malignancy.
Ethics
Written informed consent was obtained from all patients.
The study has been approved by the scientific ethical com-
mittee in the study area (KF01-384/95).
Statistical analyses
Statistical comparisons between groups were carried out
using Chi-square or rank sum tests. Association between
YKL-40 tissue expression levels and plasma YKL-40 levels
was assessed using the Spearman correlation. The clinical
endpoint in the OC patients was survival determined as
the time from baseline blood sample before operation to
time of death updated at August 23rd, 2007. Patients who
died from non-related OC were censored in the survival
analyses at the date of death. Cases in which patients were
alive by this date were censored. Survival probabilities
were estimated by the Kaplan-Meier method and tests for
differences between strata were done using the log-rank
statistic. Graphical presentation using Kaplan-Meier esti-
mates of survival were shown grouping the patients by
YKL-40 expression in the tumor tissue dichotomized at
5%. Graphical presentation using Kaplan-Meier estimates
of survival were shown grouping the patients by plasma
YKL-40 levels dichotomized as normal or elevated com-
pared to age-matched controls. In the univariate survival
analyses the YKL-40 expression scale in tumor tissue was
dichotomized as < 5% vs. ≥ 5% and the plasma YKL-40
levels by the actual value on the log scale (natural) (log
transformed). The multivariate Cox regression multivari-
ate analysis was based on FIGO stage, residual tumor after
primary surgery, serum CA-125, age and plasma YKL-40
levels by the actual value on the log scale (natural) (log
transformed). Confidence intervals (95% CI) were based
on Wald's test statistic for the corresponding parameters
in the Cox regression model, i.e. on the log-scale for the
hazard ratios (HR). Model assessment was done using
graphical methods, Schoenfeld and martingale residuals.
P-values less than 5% were considered significant. All cal-
culations were performed using SAS (version 9.1, SAS
Institute, Cary, NC, USA).
Results
YKL-40 protein expression in borderline ovarian tumors 
and in ovarian cancer tissue
Tissue arrays for YKL-40 immunohistochemical analysis
were available from 181 patients with borderline ovarian
tumors (median age 54 years, range 33 – 80) and from
473 patients with OC (median age 59 years, range 26 –
80).
The distribution of the YKL-40 score in the borderline
ovarian tumors was: level 1 (negative): 44 (24%); level 2:
74 (41%); level 3: 35 (19%) and level 4: 28 (16%). The
distribution of the YKL-40 score in the OC samples was:
level 1 (negative): 112 (24%); level 2: 101 (21%); level 3:
138 (29%) and level 4: 122 (26%). Figure 1 illustrates rep-
resentative examples of the different levels of YKL-40
staining in borderline ovarian tumors and OC. The cancer
cells showed a diffuse granular staining of the cytoplasm.
Staining of membranes and nuclei were not observed.
Borderline ovarian tumors appeared with the same stain-
ing pattern as the carcinomas, but with reduced staining
intensity (Figure 1, b–d). YKL-40 protein expression was
found in all the different histological types of OC (Figure
1). The YKL-40 protein was also expressed in inflamma-
tory cells such as macrophages, mast cells and neu-
trophils. These results have been confirmed by double-
labeling methods verifying co-expression of YKL-40 and
tryptase (mast cells) and CD68 (macrophages), respec-
tively (data not shown).
The association between clinico-pathological variables
and YKL-40 score is shown in Table 1 and Table 2. The
YKL-40 protein expression (staining percentage scale) in
OC was associated with FIGO stage (p < 0.0001) and his-
tological type of tumor (p < 0.0001), and the YKL-40
expression (staining percentage scale) was higher in the
OC than in the borderline tumors (p = 0.0019). Also a
tendency towards a correlation between reduced YKL-40
BMC Cancer 2009, 9:8 http://www.biomedcentral.com/1471-2407/9/8
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Immunohistochemical analysis of YKL-40 protein expression in paraffin-sections of different types of ovarian tumor tissue (×40)Figure 1
Immunohistochemical analysis of YKL-40 protein expression in paraffin-sections of different types of ovarian 
tumor tissue (×40). A positive immunostaining appears as a cytoplasmic, granular brown-colored staining. a: Normal ovarium 
surface epithelium, no staining; b: borderline serous tumor, no staining; c: borderline mucinous tumor, no staining, d: border-
line mucinous tumor, 30% positivity; e: well-differentiated serous adenocarcinoma, 50% positivity; f: well-differentiated muci-
nous adenocarcinom, no staining; g: moderately differentiated serous adenocarcinoma, 30% positivity; h: moderately 
differentiated mucinous adenocarcinoma, 40% positivity; i: moderately differentiated clear cell carcinoma, 40% positivity; k: 
moderately differentiated endometroid adenocarcinoma, 70% positivity; l: moderately differentiated serous adenocarcinoma, 
70% positivity; and m: moderately differentiated endometroid adenocarcinoma, 80% positivity.
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protein expression and radicality of surgery was observed
(p = 0.05).
The highest frequency of any level of positivity of YKL-40
protein expression was observed in serous adenocarcino-
mas, where 123 out of 249 tissues were scored positive
(49%).
Preoperative plasma YKL-40 in patients with borderline 
ovarian tumors and in OC
Plasma samples for YKL-40 analysis were available from
19 patients with borderline ovarian tumors (median age
45 years, range 38 – 76 years) and from 76 patients with
OC (median age 63 years, range 37 – 79 years). The
median preoperative plasma level of YKL-40 in the OC
patients was 125 μg/l (range 20 – 2650 μg/l) and signifi-
cantly higher than the level in 144 healthy women
Table 1: Clinical characteristics and YKL-40 expression in tumor tissue and plasma YKL-40 levels from patients diagnosed with 
borderline ovarian tumor#
Characteristic YKL-40 protein expression (N = 181) Plasma YKL-40 (μg/l) (N = 19)
N (%) Median (range) N (%) Median (range)
FIGO stage:
I 160 (88) 5 (0–90) 19 (100) 42 (20–180)
II 5 (3) 5 (0–30)
III 16 (9) 7.5 (0–30)
Histological type of tumor:
Cystadenoma (NOS), borderline 14 (8) 7.5 (5–20) 2 (10) 39 (38–40)
Serous cystadenoma, borderline 95 (52) 5 (0–80) 6 (32) 42 (31–142)
Mucinous cystadenoma, borderline 69 (38) 5 (0–90) 11 (58) 37 (20–180)
Endometroid cystadenoma, borderline 3 (2) 5 (5–40)
# Scoring of YKL-40 expression was based on the proportion of cells in a given tumor specimen exhibiting distinct cytoplasmic immunopositivity as 
well as intensity of staining percentage scale: 0, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, and 100. The YKL-40 scoring results was transformed into a 
four-tiered scale: 1 = negative; 2 = 5% positive tumor cells; 3 = 10% positive tumor cells and 4 = 20% or more positive tumor cells.
Table 2: Clinical characteristics and YKL-40 expression in tumor tissue and plasma YKL-40 levels from patients diagnosed with ovarian 
cancer#
Characteristic YKL-40 protein expression (N = 473) Plasma YKL-40 (μg/l) (N = 76)
N (%) Median (range) N (%) Median (range)
FIGO stage:
I 157 (33) 10 (0–90) 17 (22) 59 (20–340)
II 48 (10) 5 (0–30) 4 (5) 53 (39–259)
III 245 (52) 10 (0–70) 47 (62) 168 (32–1808)
IV 23 (5) 20 (5–40) 8 (11) 320 (86–2650)
Histological type of tumor:
Undifferentiated carcinoma 9 (2) 20 (0–40) 3 (4) 576 (156–1808)
Adenocarcinoma (NOS) 23 (5) 10 (0–30) 5 (6) 452 (237–2650)
Serous adenocarcinoma 249 (53) 5 (0–70) 50 (66) 112 (20–548)
Mucinous adenocarcinoma 53 (11) 10 (0–80) 7 (9) 102 (20–856)
Endometroid adenocarcinoma 69 (15) 10 (0–90) 8 (11) 93 (29–193)
Clear-cell neoplasm 46 (10) 10 (0–40) 2 (3) 220 (59–380)
No information - - 1 (1) 340
Histological grade of tumor:
Grade 1 124 (26) 10 (0–60) 17 (22) 61 (20–356)
Grade 2 165 (35) 10 (0–80) 27 (36) 162 (32–856)
Grade 3 183 (39) 10 (0–90) 26 (34) 144 (20–2650)
No information - - 6 (8) 360 (29–1808)
# Scoring for YKL-40 expression was based on the proportion of cells in a given tumor specimen exhibiting distinct cytoplasmic immunopositivity 
as well as intensity of staining percentage scale: 0, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, and 100. The YKL-40 scoring results was transformed into a 
four-tiered scale: 1 = negative; 2 = 5% positive tumor cells; 3 = 10% positive tumor cells and 4 = 20% or more positive tumor cells.
BMC Cancer 2009, 9:8 http://www.biomedcentral.com/1471-2407/9/8
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(median 32 μg/l, range 20 – 143 μg/l; p < 0.001). 67%
(51/76) of the OC patients had a plasma YKL-40 level
above the age-adjusted 95th percentile of the healthy
women. Patients with borderline ovarian tumors did not
have elevated plasma YKL-40 (median 42 μg/l, range 20 –
180 μg/l) compared to healthy women. 21% (4/19) of the
patients with borderline tumors had a plasma YKL-40
level above the age-adjusted 95th percentile of the healthy
women. Table 1 and Table 2 gives the relationship
between preoperative plasma YKL-40 and standard clini-
cal-pathological variables. Plasma YKL-40 increased with
increasing FIGO stage among OC patients (p = 0.0001).
Furthermore, plasma YKL-40 was correlated with serum
CA-125 (Spearmans rho = 0.47, p < 0.0001) and age (rho
= 0.59, p < 0.0001). No correlation was found between
plasma YKL-40 and the YKL-40 tissue expression percent-
age score (rho = 0.032, p = 0.081).
YKL-40 expression in OC and prognosis
Univariate survival analysis demonstrated that YKL-40 tis-
sue expression (negative or ≥ 5% positive tumor cells) was
not associated with survival (HR = 1.2; 95% CI: 0.95 –
1.53) (Figure 2). Similarly, using the four-tiered scale YKL-
40 tissue expression was confirmed of no evidence of sep-
aration (data not shown). Including YKL-40 tissue expres-
sion (negative or ≥ 5% positive tumor cells) in a
multivariate Cox regression analysis with FIGO stage,
patient age, radicality of surgery and serum CA-125 as
other parameters, showed no prognostic impact of YKL-
40 tissue expression (HR = 0.97; 95% CI: 0.99 – 1.01)
(data not shown).
Plasma YKL-40 and prognosis
During follow-up 55 (72%) of the 76 OC patients died.
Univariate Cox analysis of plasma YKL-40 (log trans-
formed and treated as a continuous covariate) showed sig-
nificant association with overall survival (HR = 2.85, 95%
CI: 2.04 – 3.97, p < 0.0001). Univariate Cox analysis of
plasma YKL-40 (dichotomized as normal vs. high age-cor-
rected plasma YKL-40 level) showed also significant asso-
ciation with overall survival (HR = 3.51, 95% CI: 1.82 –
6.75, p < 0.0001). Figure 3 illustrates the Kaplan-Meier
estimates of survival stratified by baseline plasma YKL-40
dichotomized as normal vs. high age-corrected plasma
YKL-40 level.
Performing a multivariate Cox analysis including plasma
YKL-40 (log transformed and treated as a continuous cov-
ariate), serum CA-125 (log transformed and treated as a
continuous covariate), FIGO stage (I-IV), residual tumor
Kaplan-Meier survival curves showing the association between YKL-40 protein expression and overall survivalFigure 2
Kaplan-Meier survival curves showing the association between YKL-40 protein expression and overall survival. 
YKL-40 is dichotomized in cellular percentage score in two groups (< 5% vs. ≥ 5% positivity og the cancer cells).
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after surgery (yes or no), and age showed that only plasma
YKL-40 (HR = 2.13, 95% CI: 1.40 – 3.25, p = 0.0004) was
found of independent prognostic value of overall survival.
Age at surgery (HR = 1.02, 95% CI: 0.99 – 1.06), radicality
after primary surgery (HR = 1.20, 95% CI: 0.44 – 3.33),
serum CA-125 (HR = 1.08, 95% CI: 0.94 – 1.23) and
FIGO stage (p = 0.63, FIGO 1 vs 4: HR = 0.61, 95% CI:
0.11 – 3.34, FIGO 2 vs 4: HR = 0.25, 95% CI: 0.03–2.37,
FIGO 3 vs 4: HR = 0.66, 95% CI: 0.28–1.58) were found
of no independent prognostic value in OC patients.
Discussion
In the present study we found YKL-40 protein expression
in OC cells with a higher expression score in OC than in
borderline tumors, and a clear association with FIGO
stage and type of histology, but not with survival. We used
tissue micro array with a tissue core diameter of 2.0 mm,
but although this is comparatively large we do not know
whether the degree of heterogeneity of YKL-40 protein
expression in OC tissue could have influenced our results.
This was, however, not the case in an immunohistochem-
ical analysis of YKL-40 protein expression in tissue micro
arrays of breast cancer [18]. Our present results of OC are
in accordance with this study of breast cancer, where no
association was found between YKL-40 score and progno-
sis [18]. However, this is in contrast to tumor samples
from glioblastomas, where YKL-40 acted as a biomarker of
genetic and histological subtypes, radiation therapeutic
response and prognosis [11,12,14,29,30]. Pair-wise com-
binations of markers have identified epidermal growth
factor receptor variant III (EGFRvIII) and YKL-40 as prog-
nostically important in patients with glioblastoma, pro-
viding patients with EGFRvIII-negative/YKL-40-negative
tumours with the best prognosis [29].
There are no published studies on YKL-40 protein expres-
sion in OC tissue, and to our knowledge no publications
exist on a close association between serum YKL-40, serum
CA-125 and CA15-3 in patients with OC [23-26]. It has
previously been shown that preoperative serum or plasma
concentrations of YKL-40 are elevated in 65% of patients
with FIGO stage I and II, and in 74% to 91% of patients
with FIGO stage III and IV [23,24]. In addition, patients
with high serum or plasma levels of YKL-40 with early-
Kaplan-Meier survival curves showing the association between preoperative plasma YKL-40 and overall survivalFigure 3
Kaplan-Meier survival curves showing the association between preoperative plasma YKL-40 and overall sur-
vival. Plasma YKL-40 is dichotomized in normal vs. elevated plasma YKL-40 levels. The cut-off point is the age-adjusted plasma 
YKL-40 value corresponding to the 95th percentile in healthy controls. The P-value refers to the log-rank test for equality of 
strata.
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stage OC [24], stage III [23], or recurrent of OC [25] had
shorter survival than OC patients with normal levels of
YKL-40.
In the present study plasma was available from a small
subgroup of patients with borderline ovarian tumors and
OCs, and in accordance with the studies mentioned above
[23-26] we also found that elevated preoperative plasma
concentrations of YKL-40 significantly predicted short sur-
vival in patients with OC. However, we did not find any
correlation between plasma and tissue score YKL-40 in
corresponding tissue and YKL-40 level in plasma samples
in this subgroup of OC patients. Two persons simultane-
ously assessed the patterns of YKL-40 protein expression
of each tumor sample and discussed each sample if result
were not concordant. It is often the case that there is no
correlation between protein expression in cancer tissue
and circulating levels of the protein. The reason for this
observation is possibly due to a considerable contribution
to the plasma YKL-40 level from the many tumor-associ-
ated inflammatory cells, which also produce the protein
[21,22]. Perhaps the YKL-40 production of inflammatory
cells in tumor tissue are linked to or reflect a more malig-
nant phenotype of the tumor, thus contributing to the ele-
vated plasma YKL-40 levels observed in patients with a
poor prognosis.
Conclusion
In conclusion, this study has shown that YKL-40 is
expressed in OC cells, and a high expression is associated
with a high FIGO stage and histological type of tumor. In
contrast to plasma YKL-40, high tumor cell expression of
the protein was not associated with poor prognosis. This
may be due to contribution to the plasma YKL-40 level
from tumor-associated inflammatory cells, which also
produce the protein.
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